Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Market Chatter: Oracle Cites Force Majeure as New Mexico Data Center Faces Delays

Market Chatter: Oracle Cites Force Majeure as New Mexico Data Center Faces Delays

MT newswireMT newswire2026/09/24 13:41
09:41 AM EDT, 09/24/2026 (MT Newswires) -- Oracle (ORCL) issued a force majeure notice to Project Jupiter's developer, a unit of Blue Owl Capital (OWL), seeking to defer payments if its planned New Mexico data center is delayed and fails to come online in 2028 as planned, Bloomberg reported Thursday, citing people familiar with the matter. According to the report, Oracle is not seeking to exit the project but is protecting its contractual position if construction is delayed, while saying Project Jupiter remains on schedule and that it remains fully committed to New Mexico. The 2.45-gigawatt data-center campus has faced regulatory setbacks, with the natural gas pipeline intended to supply the project delayed by nearly six months, to Feb. 1, 2027, following repeated permit denials by the New Mexico State Land Office, Bloomberg added. Oracle shares were down 4% in premarket activity. Oracle did not immediately respond to requests for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 137.53, Change: -7.01, Percent Change: -4.85
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26